Compare Enveric Biosciences Inc (ENVB) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Direxion Daily S&P 500 Bull 3X Shares trades at $295.49 (market cap $7.36B). The key difference: Direxion Daily S&P 500 Bull 3X Shares is far larger — about 1082.4× Enveric Biosciences Inc's market cap, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Direxion Daily S&P 500 Bull 3X Shares for 32 Days on average.
| ENVB | SPXL | |
|---|---|---|
Market Cap | $6.80M | $7.36B |
Volume | 64,867 | 1,835,467 |
Sector | Health | Leveraged / Inverse |
52-Week High | $10.80 | $301.38 |
52-Week Low | $1.27 | $170.20 |
Typical Hold Time | 14 Days | 32 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
SPXL trades at $296.84, down 0.79% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF maintains neutral oscillator signals while approaching key resistance at $299. Recent market sentiment reflects mixed outlooks for S&P 500 performance amid earnings growth concerns and seasonal patterns.
The leveraged ETF's performance remains tied to S&P 500 movements, with Wall Street projecting potential upside but facing headwinds from expected earnings growth slowdown. Key risks include market concentration in top holdings and geopolitical uncertainties affecting broader market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
